It is being hailed as one of the biggest advances in biology in decades, one that could eventually lead to drugs for a wide range of diseases, from cancer to diabetes to AIDS. And one startup, Cambridge, MA-based Alnylam Pharmaceuticals, is in a particularly strong position to transform it into new pharmaceuticals.

Select from the choices above to read the entire article.